GlassScriptPhysician profile
Jennifer Carter
NPI 1841636214
$805.03
in general payments reported to CMS, 2019-2025
20 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.03 · 2020: $318 · 2021: $22.59 · 2022: $16.00 · 2024: $250 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $129.26 | 2020 | |
| Stemline Therapeutics INC. | $125.00 | 2024 | Orserdu |
| Incyte Corporation | $124.99 | 2025 | Jakafi |
| Emd Serono, INC. | $62.80 | 2024 | |
| Daiichi Sankyo INC. | $41.32 | 2020 | |
| Merck Sharp & Dohme LLC | $34.20 | 2020-2025 | Keytruda Qlex, Keytruda, Welireg |
| Pfizer INC. | $31.42 | 2024 | |
| Rigel Pharmaceuticals, INC. | $30.98 | 2024 | Tavalisse, Rezlidhia |
| Eisai INC. | $23.87 | 2020 | |
| Janssen Biotech, INC. | $23.29 | 2025 | Rybrevant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.59 | 2021 | |
| Astellas Pharma US INC | $20.29 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.62 | 2020 | |
| Amgen INC. | $19.53 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $18.25 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $16.44 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.03 | 2019 | |
| Adaptive Biotechnologies Corporation | $16.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.34 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.